Combined immunosuppressants and less steroids in active graves' orbitopathy?. (9th January 2019)

• Record Type: Journal Article
• Authors: Salvi, Mario; Covelli, Danila
• Is Part Of: Clinical endocrinology. Volume 90:Number 4(2019)
• Page Start: 525
• Page End: 527
• Publication Date: 2019-01-09
• Subjects: Graves' Orbitopathy -- immunosuppression -- methotrexate -- methylprednsolone -- rituximab; Endocrinology -- Periodicals; 616.4005
• DOI: 10.1111/cen.13917
• Languages: English
• ISSNs: 0300-0664

Abstract

Abstract: Steroid therapy in GO is first‐line treatment but has limitations, as it is potentially harmful at high doses and often refused by patients. A steroid‐sparing therapy is a reasonable option as long as it is rapidly effective and devoid of long‐term adverse reactions. Combined immunosuppressive therapy must be studied in randomized clinical trials designed to test efficacy and the potentially increased risk of side effects.